Study: NCT00440726

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bortezomib
Description: Intravenous on days 1, 4, 8 and 11. Dose assigned at study entry.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg/m2/day divided BID, oral administration for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 10 mg/m2/day divided BID, oral administration for 14 days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: 2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PEG-asparaginase
Description: 2500 IU/m2/day, intramuscular injection on Days 2, 8, 15 and 22

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2/day IV over 15 minutes on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxorubicin
Description: 60 mg/m2/day IV over 15 minutes on Day 1

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally on Day 1 of course 1 at the dose defined by age below.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Given intrathecally on Day 1 of course 1 at the dose defined by age below.~* 30 mg for patients age 1-1.99~* 50 mg for patients age 2-2.99~* 70 mg for patients \>3 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: Given intrathecally to all patients who are CNS 1 at study entry on Day 15 at the dose defined by age below.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients \>9 years of age

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vincristine
Description: 1.5 mg/m2/dose IV push (maximum single dose 2 mg) on Days 1, 8, 15 and 22.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple IT Therapy
Description: Triple IT therapy will be given intrathecally on Day 8, 15, and 22 for patients who are CNS 2 and CNS 3 at study entry. Regimen/dosing as follows:~Methotrexate-~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* \>=9 y: 15 mg~Cytarabine:~* \<2 years: 16 mg~* 2 - \<3 y: 20 mg~* 3 - \<9 y: 24 mg~* \>=9 y: 30 mg~Hydrocortisone:~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* \>=9 y: 15 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Triple IT Therapy
Description: Triple IT therapy will be given intrathecally on Day 8, 15, and 22 for patients who are CNS 2 and CNS 3 at study entry. Regimen/dosing as follows:~Methotrexate-~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* \>=9 y: 15 mg~Cytarabine:~* \<2 years: 16 mg~* 2 - \<3 y: 20 mg~* 3 - \<9 y: 24 mg~* \>=9 y: 30 mg~Hydrocortisone:~* \<2 years: 8 mg~* 2 - \<3 y: 10 mg~* 3 - \<9 y: 12 mg~* \>=9 y: 15 mg